ARTICLE | Product Development
Chinese biotechs look to next-generation CAR T technologies to solve market challenges
Chinese CAR T cell companies are mapping out solutions to their cost problem
April 2, 2021 9:42 PM UTC
Though nearly every Chinese CAR T developer is prioritizing autologous programs, the key to expanding access to the modality on the price-sensitive China market is likely to be the next-generation platforms these companies are quietly building.
These second-generation technologies — many designed with cost-cutting in mind — range from protocols to compress manufacturing timelines to off-the-shelf products that can be produced at scale...